Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score

References

• Lynch DT, Koya S, Acharya U. Mantle cell lymphoma. StatPearls, Treasure Island (FL): statPearls Publishing; 2022.
   Google Scholar
• Birgitta S. Mantle cell lymphoma. Semin Cancer Biol. 2011;21:291–292.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the second nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival Plateau. Br J Haematol. 2016;175(3):410–418.
   PubMed Web of Science ®Google Scholar
• Liebers N, Dreger P, Dreyling M, et al. Risk stratification of mantle cell lymphoma (MCL). Ann Lymphoma. 2018;2:10–10.
   Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
   PubMed Web of Science ®Google Scholar
• Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European Mantle-cell lymphoma network. J Clin Oncol. 2014;32(13):1338–1346.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. The mantle cell lymphoma international prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010;115(8):1530–1533.
   PubMed Web of Science ®Google Scholar
• Chihara D, Asano N, Ohmachi K, et al. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan. Br J Haematol. 2015;170(5):657–668.
   PubMed Web of Science ®Google Scholar
• Salek D, Vesela P, Boudova L, et al. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of mantle cell lymphoma international prognostic index and ki-67 in the era of rituximab: long-term data from the czech lymphoma project database. Leuk Lymphoma. 2014;55(4):802–810.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of ki-67 index, cytology, and growth pattern in Mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• Croci GA, Hoster E, Beà S, et al. Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. Virchows Arch. 2020;477(2):259–267.
   PubMed Web of Science ®Google Scholar
• Nordström L, Sernbo S, Eden P, et al. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic lymphoma group study. Br J Haematol. 2014;166(1):98–108.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.
   PubMed Web of Science ®Google Scholar
• Scott DW, Abrisqueta P, Wright GW, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35(15):1668–1677.
   PubMed Web of Science ®Google Scholar
• Holte H, Beiske K, Boyle M, et al. The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy. Br J Haematol. 2018;183(2):225–234.
   PubMed Web of Science ®Google Scholar
• Rauert-Wunderlich H, Mottok A, Scott DW, et al. Validation of the MCL35 gene expression proliferation assay in randomized trials of the European mantle cell lymphoma network. Br J Haematol. 2019;184(4):616–624.
   PubMed Web of Science ®Google Scholar
• Freeman CL, Pararajalingam P, Jin L, et al. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia. 2022;36(10):2479–2487.
   PubMed Web of Science ®Google Scholar
• Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–338.
   PubMed Web of Science ®Google Scholar
• Vo JN, Cieslik M, Zhang Y, et al. The landscape of circular RNA in cancer. Cell. 2019;176(4):869–881.e13.
   PubMed Web of Science ®Google Scholar
• Dahl M, Husby S, Eskelund CW, et al. Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia. 2022;36(1):177–188.
   PubMed Web of Science ®Google Scholar
• Dahl M, Daugaard I, Andersen MS, et al. Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. Lab Invest. 2018;98(12):1657–1669.
   PubMed Web of Science ®Google Scholar
• Kristensen LS. Profiling of circRNAs using an enzyme-free digital counting method. Methods. 2021;196:11–16.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic lymphoma group. Blood. 2008;112(7):2687–2693.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood. 2014;123(19):2953–2959.
   PubMed Web of Science ®Google Scholar
• Husby S, Ralfkiaer U, Garde C, et al. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. Blood. 2015;125(17):2669–2677.
   PubMed Web of Science ®Google Scholar
• Mishra A, Verma M. Cancer biomarkers: are we ready for the prime time? Cancers. 2010;2(1):190–208.
   PubMedGoogle Scholar
• Charilaou P, Battat R. Machine learning models and over-fitting considerations. World J Gastroenterol. 2022;28(5):605–607.
   PubMed Web of Science ®Google Scholar
• Klapper W, Hoster E, Determann O, et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL network. J Hematop. 2009;2(2):103–111.
   PubMedGoogle Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
   PubMed Web of Science ®Google Scholar
• Clot G, Jares P, Giné E, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood. 2018;132(4):413–422.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Sestak I, Lopez-Knowles E, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol. 2013;31(22):2783–2790.
   PubMed Web of Science ®Google Scholar
• Hannouf MB, Brezden-Masley C, Raphael J, et al. A review of gene expression profiling in early-stage ER+/HER2-breast cancer with a focus on The PAM50 risk of recurrence assay. EMJ Oncol. 2019;7:2–13.
   Google Scholar
• Robetorye RS, Ramsower CA, Rosenthal AC, et al. Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B-Cell lymphoma. J Hematop. 2019;12(1):3–10.
   PubMed Web of Science ®Google Scholar
• Zamò A, Gerhard-Hartmann E, Ott G, et al. Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series. Virchows Arch. 2022;481(6):935–943.
   PubMed Web of Science ®Google Scholar
• Tsang H-F, Xue VW, Koh S-P, et al. NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics. Expert Rev Mol Diagn. 2017;17(1):95–103.
   PubMed Web of Science ®Google Scholar
• Chen L-L. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205–211.
   PubMed Web of Science ®Google Scholar
• Xi X, Li T, Huang Y, et al. RNA biomarkers: frontier of precision medicine for cancer. ncRNA. 2017;3(1):9.
   Google Scholar